Wedbush Maintains Outperform on Disc Medicine, Raises Price Target to $100
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Wedbush analyst David Nierengarten maintains Disc Medicine (NASDAQ:IRON) with a Outperform and raises the price target from $88 to $100.
Wedbush analyst David Nierengarten maintains Disc Medicine (NASDAQ:IRON) with a Outperform and raises the price target from $88 to $100.